Related Experiment Video
Updated: Nov 26, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
Shalini Arunogiri1, Nicholas Lintzeris2
1Turning Point, Eastern Health, Richmond, VIC 3121, Australia; Monash Alfred Psychiatry Research Centre and Monash Addiction Research Centre, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3004, Australia.
Abstract:
The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.
Related Concept Videos
Drug Dependence
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Abuse and Addiction: Pharmacological Phenomena
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
CNS Depressants: Barbiturates and Benzodiazepines

